Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more
Amotiv Limited (AOV) - Total Liabilities
Latest total liabilities as of September 2025: CA$281.78 Million CAD
Based on the latest financial reports, Amotiv Limited (AOV) has total liabilities worth CA$281.78 Million CAD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amotiv Limited - Total Liabilities Trend (2014–2024)
This chart illustrates how Amotiv Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Amotiv Limited Competitors by Total Liabilities
The table below lists competitors of Amotiv Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Zhongbai Co Ltd
SHG:600857
|
China | CN¥87.89 Million |
|
Partron Co. Ltd
KQ:091700
|
Korea | ₩211.53 Billion |
|
CASIN Real Estate Development Group Co Ltd
SHE:000838
|
China | CN¥2.05 Billion |
|
Assystem S.A.
PA:ASY
|
France | €391.10 Million |
|
Agesa Hayat ve Emeklilik AS
IS:AGESA
|
Turkey | TL396.50 Billion |
|
CyberTAN Technology Inc
TW:3062
|
Taiwan | NT$2.05 Billion |
|
Daou Data Corp
KQ:032190
|
Korea | ₩67.26 Trillion |
Liability Composition Analysis (2014–2024)
This chart breaks down Amotiv Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.05 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amotiv Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amotiv Limited (2014–2024)
The table below shows the annual total liabilities of Amotiv Limited from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$168.69 Million | -15.07% |
| 2023-12-31 | CA$198.62 Million | -13.26% |
| 2022-12-31 | CA$228.98 Million | +52.78% |
| 2021-12-31 | CA$149.87 Million | -2.32% |
| 2020-12-31 | CA$153.44 Million | -60.68% |
| 2019-12-31 | CA$390.20 Million | +1689.89% |
| 2018-12-31 | CA$21.80 Million | +47.55% |
| 2017-12-31 | CA$14.78 Million | +33.69% |
| 2016-12-31 | CA$11.05 Million | +59.57% |
| 2015-12-31 | CA$6.93 Million | -9.14% |
| 2014-12-31 | CA$7.62 Million | -- |